Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
$2.50
-2.3%
$0.00
$2.28
$24.15
$46.75M0.4838,957 shs35,701 shs
NVLNF
Novelion Therapeutics
$0.70
-1.2%
$0.70
$0.51
$1.00
$13.77M2.15261,364 shs26,900 shs
PepGen, Inc. stock logo
PEPG
PepGen
$1.22
+0.8%
$1.44
$0.88
$19.30
$39.92M1.16844,504 shs152,259 shs
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
$0.10
-5.1%
$0.10
$0.00
$0.08
$54.70M10.91.01 million shs15,021 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
0.00%-4.58%-19.61%+249,999,900.00%+249,999,900.00%
NVLNF
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%
PepGen, Inc. stock logo
PEPG
PepGen
0.00%+6.09%-14.08%+11.42%-92.69%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
+0.18%-0.32%-7.18%+98.36%-31.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
2.9401 of 5 stars
3.23.00.00.01.82.51.3
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
0.00
N/AN/AN/A
NVLNF
Novelion Therapeutics
0.00
N/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
2.33
Hold$7.67528.42% Upside
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVLNF, TRUU, PEPG, and KLRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
PepGen, Inc. stock logo
PEPG
PepGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $8.00
5/9/2025
PepGen, Inc. stock logo
PEPG
PepGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $14.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/A$22.47 per shareN/A
NVLNF
Novelion Therapeutics
$130.43M0.11N/AN/A($4.69) per share-0.15
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/A$3.64 per shareN/A
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
$1.95M252.92N/AN/A($0.03) per share-3.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
-$58.77MN/A0.00N/AN/A-62.08%-54.69%N/A
NVLNF
Novelion Therapeutics
-$108.33MN/A0.00N/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
-$89.98M-$3.13N/AN/AN/AN/A-81.26%-63.65%8/6/2025 (Estimated)
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
-$3.88M$0.019.92N/A-255.80%N/A-165.86%N/A

Latest NVLNF, TRUU, PEPG, and KLRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
PepGen, Inc. stock logo
PEPG
PepGen
-$0.72-$0.92-$0.20-$0.92N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
N/AN/AN/AN/AN/A
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/A
14.31
14.31
NVLNF
Novelion Therapeutics
N/AN/AN/A
PepGen, Inc. stock logo
PEPG
PepGen
N/A
4.95
4.95
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/A
0.01
N/A

Institutional Ownership

CompanyInstitutional Ownership
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
66.05%
NVLNF
Novelion Therapeutics
48.64%
PepGen, Inc. stock logo
PEPG
PepGen
58.01%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
N/A

Insider Ownership

CompanyInsider Ownership
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
74.99%
NVLNF
Novelion Therapeutics
3.60%
PepGen, Inc. stock logo
PEPG
PepGen
5.20%
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
18.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
11018.70 million4.68 millionN/A
NVLNF
Novelion Therapeutics
10919.62 millionN/ANot Optionable
PepGen, Inc. stock logo
PEPG
PepGen
3032.72 million31.02 millionNot Optionable
True Drinks Holdings, Inc stock logo
TRUU
True Drinks
404.97 billionN/ANot Optionable

Recent News About These Companies

Beer News: True Acts Of Aletruism / New “Indie Beer” Campaign
Review: True Story Finished Bourbon
Vitalizes Body and Mind.®
PD TRUE : STREAM IT OR SKIP IT?
10 Drinks People Fake Liking to Fit In
16 Best Summer Cocktails for a Hot Weather Buzz

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kalaris Therapeutics stock logo

Kalaris Therapeutics NASDAQ:KLRS

$2.50 -0.06 (-2.34%)
As of 07/3/2025 01:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Novelion Therapeutics OTCMKTS:NVLNF

$0.70 -0.01 (-1.20%)
As of 01/16/2020

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

PepGen stock logo

PepGen NASDAQ:PEPG

$1.22 +0.01 (+0.83%)
Closing price 07/3/2025 02:21 PM Eastern
Extended Trading
$1.24 +0.02 (+1.64%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

True Drinks stock logo

True Drinks OTCMKTS:TRUU

$0.10 -0.01 (-5.07%)
As of 07/3/2025

True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.